Vascular Perfusion Solutions

Executive Summary

Vascular Perfusion Solutions is a San Diego-based medical device company developing the VP.S ENCORE®, a portable hypothermic oxygenated perfusion system designed to extend the preservation time of donor hearts. Unlike current preservation methods that rely on cold static storage or blood-based perfusion, the VP.S ENCORE uses a blood-free, oxygenated perfusate to maintain organ viability for longer periods, potentially overcoming logistical barriers in heart transplantation. The device has received FDA Breakthrough Device Designation, reflecting its potential to address a significant unmet need in transplant medicine. Currently in preclinical evaluation, the company is focused on generating pivotal data to support an Investigational Device Exemption (IDE) submission. With heart transplant waitlists increasing and donor organ shortage persisting, a reliable extended preservation solution could dramatically expand the donor pool and improve transplant outcomes. The company's differentiated approach—simplicity, portability, and blood-free operation—positions it as a promising player in the organ preservation space, though it remains early-stage with regulatory and clinical validation milestones ahead.

Upcoming Catalysts (preview)

• Q2 2026Completion of pivotal preclinical study75% success
• Q4 2026FDA IDE submission60% success
• Q2 2027Initiation of first-in-human clinical trial40% success